



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	373634	AdrenaForte
ARTG entry for	Medicine Listed	
Sponsor	RN Labs Pty Ltd	
Postal Address	18 / 93 Rivergate Place, MURARRIE, QLD, 4172 Australia	
ARTG Start Date	27/08/2021	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . AdrenaForte

Product Type	Single Medicine Product	Effective Date	27/08/2021
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Enhance/promote/physical endurance/capacity/stamina
Enhance/promote body adaptation to stress
Enhance/improve/promote/increase cognitive performance
Maintain/support general mental wellbeing
Maintain/support nervous system health

Indication Requirements

Product presentation must not imply or refer to mental illnesses, disorders or conditions.
Product presentation must not imply or refer to chronic fatigue syndrome.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

No Warnings included on Record

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule
------------------	------------------------

Components

1 . Formulation 1

Dosage Form	Capsule, hard
Route of Administration	Oral
Visual Identification	

Public Summary



Australian Government
Department of Health
Therapeutic Goods Administration

Active Ingredients

Ginkgo biloba leaf Extract dry concentrate	100 mg
Equivalent: Ginkgo biloba (Dry)	5 g
Glycyrrhiza glabra root Extract dry concentrate	75 mg
Equivalent: Glycyrrhiza glabra (Dry)	600 mg
Panax ginseng root Extract dry concentrate	200 mg
Equivalent: Panax ginseng (Dry)	2 g
sodium ascorbate	113 mg
Equivalent: ascorbic acid	100 mg

Other Ingredients (Excipients)

colloidal anhydrous silica
hypromellose
leucine
silicified microcrystalline cellulose

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary